This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tentori, L. Articles by Graziani, G. Search for Related Content PubMed PubMed Citation Articles by Tentori, L. Articles by Graziani, G.

Systemic Administration of GPI 15427, a Novel Poly(ADP-Ribose) Polymerase-1 Inhibitor, Increases the Antitumor Activity of Temozolomide against Intracranial Melanoma, Glioma, Lymphoma

Department of Neuroscience, University of Rome "Tor Vergata," Rome, Italy [L. T., M. V., I. P., G. G.]; Experimental Prelinical Laboratory, Regina Elena Institute for Cancer Research, Rome, Italy [C. L., M. S., G. Z.]; Department of Experimental Medicine and Pathology, University of Rome "La Sapienza," Rome, Italy [G. d’A.]; and Guilford Pharmaceuticals, Inc., Baltimore, Maryland [W. X., V. K., J. Z.]

Purpose: Temozolomide (TMZ) is a DNA methylating agent that has shown promising antitumor activity in recent clinical trials against high grade gliomas, metastatic melanoma, and brain lymphoma. In this study, we tested whether systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase (PARP-1) inhibitor capable of crossing the blood-brain barrier, could enhance the efficacy of TMZ against metastatic melanoma, glioblastoma multiforme, and lymphoma growing in the brain.

Experimental Design: Murine B16 melanoma or L5178Y lymphoma cells were injected intracranially in syngeneic mice. An orthotopic xenograft of the human SJGBM2 glioblastoma multiforme was implanted in nude mice. Animals were treated with TMZ + GPI 15427 using a schedule of 40 mg/kg/i.v. GPI 15427 + 100 mg/kg/i.p. TMZ for 3 days. The efficacy of drug treatment was assessed by: (a) the increase of mouse survival and life span; and (b) the suppression of melanoma metastases to lung after i.v. injection of B16 cells.

Results: In all models, systemic administration of GPI 15427 shortly before TMZ significantly increased life span of tumor-bearing mice with respect to untreated controls or to groups treated with either GPI 15427 or TMZ only. Moreover, GPI 15427 increased the antimetastatic effect of TMZ.

Conclusions: These data indicate that systemic administration of the poly(ADP-ribose) polymerase-1 inhibitor GPI 15427 significantly enhances TMZ antitumor efficacy against solid or hematological neoplasias even when located at the central nervous system site.

This article has been cited by other articles:

				W. W. Ma and A. A. Adjei Novel Agents on the Horizon for Cancer Therapy CA Cancer J Clin, March 1, 2009; 59(2): 111 - 137. [Abstract] [Full Text] [PDF]

				A. L. Russo, H.-C. Kwon, W. E. Burgan, D. Carter, K. Beam, X. Weizheng, J. Zhang, B. S. Slusher, A. Chakravarti, P. J. Tofilon, et al. In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016 Clin. Cancer Res., January 15, 2009; 15(2): 607 - 612. [Abstract] [Full Text] [PDF]

				K. Devalaraja-Narashimha and B. J. Padanilam PARP-1 Inhibits Glycolysis in Ischemic Kidneys J. Am. Soc. Nephrol., January 1, 2009; 20(1): 95 - 103. [Abstract] [Full Text] [PDF]

				R. Plummer, C. Jones, M. Middleton, R. Wilson, J. Evans, A. Olsen, N. Curtin, A. Boddy, P. McHugh, D. Newell, et al. Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors Clin. Cancer Res., December 1, 2008; 14(23): 7917 - 7923. [Abstract] [Full Text] [PDF]

				X. Liu, Y. Shi, R. Guan, C. Donawho, Y. Luo, J. Palma, G.-d. Zhu, E. F. Johnson, L. E. Rodriguez, N. Ghoreishi-Haack, et al. Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks Mol. Cancer Res., October 1, 2008; 6(10): 1621 - 1629. [Abstract] [Full Text] [PDF]

				J. N. Sarkaria, G. J. Kitange, C. D. James, R. Plummer, H. Calvert, M. Weller, and W. Wick Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma Clin. Cancer Res., May 15, 2008; 14(10): 2900 - 2908. [Abstract] [Full Text] [PDF]

				E. R. Plummer and H. Calvert Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 15 - 22. [Abstract] [Full Text] [PDF]

				E. R. Plummer and H. Calvert Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy Clin. Cancer Res., November 1, 2007; 13(21): 6252 - 6256. [Abstract] [Full Text] [PDF]

				C. K. Donawho, Y. Luo, Y. Luo, T. D. Penning, J. L. Bauch, J. J. Bouska, V. D. Bontcheva-Diaz, B. F. Cox, T. L. DeWeese, L. E. Dillehay, et al. ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models Clin. Cancer Res., May 1, 2007; 13(9): 2728 - 2737. [Abstract] [Full Text] [PDF]

				K. Ratnam and J. A. Low Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology Clin. Cancer Res., March 1, 2007; 13(5): 1383 - 1388. [Abstract] [Full Text] [PDF]

				L. Tentori, C. Leonetti, M. Scarsella, A. Muzi, E. Mazzon, M. Vergati, O. Forini, R. Lapidus, W. Xu, A. S. Dorio, et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma FASEB J, August 1, 2006; 20(10): 1709 - 1711. [Abstract] [Full Text] [PDF]

				S. Jones-Bolin, H. Zhao, K. Hunter, A. Klein-Szanto, and B. Ruggeri The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol. Cancer Ther., July 1, 2006; 5(7): 1744 - 1753. [Abstract] [Full Text] [PDF]

				S. S. Singhal, Y. C. Awasthi, and S. Awasthi Regression of Melanoma in a Murine Model by RLIP76 Depletion Cancer Res., February 15, 2006; 66(4): 2354 - 2360. [Abstract] [Full Text] [PDF]

				C. L. Cheng, S. P. Johnson, S. T. Keir, J. A. Quinn, F. Ali-Osman, C. Szabo, H. Li, A. L. Salzman, M. E. Dolan, P. Modrich, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft Mol. Cancer Ther., September 1, 2005; 4(9): 1364 - 1368. [Abstract] [Full Text] [PDF]

				R. N. Trivedi, K. H. Almeida, J. L. Fornsaglio, S. Schamus, and R. W. Sobol The Role of Base Excision Repair in the Sensitivity and Resistance to Temozolomide-Mediated Cell Death Cancer Res., July 15, 2005; 65(14): 6394 - 6400. [Abstract] [Full Text] [PDF]

				L. Tentori, O. Forini, E. Fossile, A. Muzi, M. Vergati, I. Portarena, C. Amici, B. Gold, and G. Graziani N3-Methyladenine Induces Early Poly(ADP-Ribosylation), Reduction of Nuclear Factor-{kappa}B DNA Binding Ability, and Nuclear Up-Regulation of Telomerase Activity Mol. Pharmacol., February 1, 2005; 67(2): 572 - 581. [Abstract] [Full Text] [PDF]